Hassan A. Sibai

Toronto, ON M5G2M9, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.

Journal: Current oncology (Toronto, Ont.)
Published: May 05, 2026

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Journal: Haematologica
Published: April 23, 2026

Thrombosis-Associated Risk Factors in Pediatrics and Adults Treated with Asparaginase-Containing Chemotherapy for ALL: A Systematic Review and Meta-Analysis.

Thrombosis-Associated Risk Factors in Pediatrics and Adults Treated with Asparaginase-Containing Chemotherapy for ALL: A Systematic Review and Meta-Analysis.

Journal: Current oncology (Toronto, Ont.)
Published: April 01, 2026

Extramedullary AML: Clinical and Molecular Features.

Extramedullary AML: Clinical and Molecular Features.

Journal: Cancers
Published: March 24, 2026

Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8.

Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8.

Journal: Hematological oncology
Published: March 12, 2026

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Journal: Current oncology (Toronto, Ont.)
Published: January 06, 2026

Gilteritinib-associated hand-foot syndrome: a novel dermatologic reaction in refractory FLT3 Acute myeloid leukemia.

Gilteritinib-associated hand-foot syndrome: a novel dermatologic reaction in refractory FLT3 Acute myeloid leukemia.

Journal: Leukemia research reports
Published: November 23, 2025

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Journal: Clinical lymphoma, myeloma & leukemia
Published: September 18, 2025

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part Two - The team and patient care experiences.

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part Two - The team and patient care experiences.

Journal: Canadian oncology nursing journal = Revue canadienne de nursing oncologique
Published: September 02, 2025

Title Not Found

Title Not Found

Journal: Canadian oncology nursing journal = Revue canadienne de nursing oncologique
Published: August 28, 2025

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One - From timeliness of triage to cost-saving.

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One - From timeliness of triage to cost-saving.

Journal: Canadian oncology nursing journal = Revue canadienne de nursing oncologique
Published: August 28, 2025

Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.

Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.

Journal: British journal of haematology
Published: August 28, 2025
Showing 1-12 of 84

Last Updated: 09/26/2026